BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29472717)

  • 1. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.
    Tefferi A; Nicolosi M; Mudireddy M; Lasho TL; Gangat N; Begna KH; Hanson CA; Ketterling RP; Pardanani A
    Leukemia; 2018 May; 32(5):1189-1199. PubMed ID: 29472717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.
    Caramazza D; Begna KH; Gangat N; Vaidya R; Siragusa S; Van Dyke DL; Hanson C; Pardanani A; Tefferi A
    Leukemia; 2011 Jan; 25(1):82-8. PubMed ID: 20944670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.
    Hidaka T; Shide K; Shimoda H; Kameda T; Toyama K; Katayose K; Kubuki Y; Nagata K; Takenaka K; Akashi K; Okamura T; Niho Y; Mizoguchi H; Omine M; Ozawa K; Harada M; Shimoda K
    Eur J Haematol; 2009 Oct; 83(4):328-33. PubMed ID: 19549278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.
    Hussein K; Pardanani AD; Van Dyke DL; Hanson CA; Tefferi A
    Blood; 2010 Jan; 115(3):496-9. PubMed ID: 19901264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.
    Tefferi A; Guglielmelli P; Nicolosi M; Mannelli F; Mudireddy M; Bartalucci N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Begna KH; Naseema Gangat ; Pardanani A; Vannucchi AM
    Leukemia; 2018 Jul; 32(7):1631-1642. PubMed ID: 29654267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conventional cytogenetics in myelofibrosis: literature review and discussion.
    Hussein K; Van Dyke DL; Tefferi A
    Eur J Haematol; 2009 May; 82(5):329-38. PubMed ID: 19141119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
    Hussein K; Huang J; Lasho T; Pardanani A; Mesa RA; Williamson CM; Ketterling RP; Hanson CA; Van Dyke DL; Tefferi A
    Eur J Haematol; 2009 Apr; 82(4):255-9. PubMed ID: 19215287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
    Guglielmelli P; Lasho TL; Rotunno G; Mudireddy M; Mannarelli C; Nicolosi M; Pacilli A; Pardanani A; Rumi E; Rosti V; Hanson CA; Mannelli F; Ketterling RP; Gangat N; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM; Tefferi A
    J Clin Oncol; 2018 Feb; 36(4):310-318. PubMed ID: 29226763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis.
    Tefferi A; Partain DK; Palmer JM; Slack JL; Roy V; Hogan WJ; Litzow ML; Ketterling RP; Patnaik MM
    Am J Hematol; 2018 May; 93(5):649-654. PubMed ID: 29388258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations and prognosis in primary myelofibrosis.
    Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
    Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.
    Tam CS; Abruzzo LV; Lin KI; Cortes J; Lynn A; Keating MJ; Thomas DA; Pierce S; Kantarjian H; Verstovsek S
    Blood; 2009 Apr; 113(18):4171-8. PubMed ID: 19131547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.
    Dingli D; Schwager SM; Mesa RA; Li CY; Dewald GW; Tefferi A
    Cancer; 2006 May; 106(9):1985-9. PubMed ID: 16568439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of Primary Myelofibrosis in the Genomic Era.
    Bose P; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S105-13. PubMed ID: 27521306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.
    Tefferi A; Guglielmelli P; Lasho TL; Rotunno G; Finke C; Mannarelli C; Belachew AA; Pancrazzi A; Wassie EA; Ketterling RP; Hanson CA; Pardanani A; Vannucchi AM
    Leukemia; 2014 Jul; 28(7):1494-500. PubMed ID: 24496303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic studies and their prognostic contribution in 565 Chinese patients with primary myelofibrosis.
    Li B; Xu J; Li C; Gale RP; Xu Z; Qin T; Zhang Y; Huang G; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
    Am J Hematol; 2014 Nov; 89(11):1043-6. PubMed ID: 25132428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A study of prognostic value of cytogenetics in patients with primary myelofibrosis].
    Li B; Xu J; Xu Z; Li C; Qin T; Fang L; Zhang H; Hu N; Pan L; Qu S; Wang J; Zhang Y; Zhang P; Xiao Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):990-4. PubMed ID: 25417875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.